The importance of monitoring for pharmacodynamic DDIs can be illustrated by potential interactions between tyrosine kinase inhibitors (TKIs), such as alectinib — indicated for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer — or dasatinib — indicated for chronic myeloid leukemia — and CV medications. The gene discussed is ALK; the disease is non-small cell lung carcinoma.